MA42196A - Particules de fumarate de diméthyle et leurs compositions pharmaceutiques - Google Patents
Particules de fumarate de diméthyle et leurs compositions pharmaceutiquesInfo
- Publication number
- MA42196A MA42196A MA042196A MA42196A MA42196A MA 42196 A MA42196 A MA 42196A MA 042196 A MA042196 A MA 042196A MA 42196 A MA42196 A MA 42196A MA 42196 A MA42196 A MA 42196A
- Authority
- MA
- Morocco
- Prior art keywords
- pharmaceutical compositions
- dimethyl fumarate
- fumarate particles
- particles
- dimethyl
- Prior art date
Links
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 title 1
- 229960004419 dimethyl fumarate Drugs 0.000 title 1
- 239000002245 particle Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562181061P | 2015-06-17 | 2015-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42196A true MA42196A (fr) | 2018-04-25 |
Family
ID=56292916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA042196A MA42196A (fr) | 2015-06-17 | 2016-06-15 | Particules de fumarate de diméthyle et leurs compositions pharmaceutiques |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11291642B2 (enExample) |
| EP (1) | EP3310341A1 (enExample) |
| JP (2) | JP2018517735A (enExample) |
| KR (1) | KR20180018711A (enExample) |
| CN (1) | CN107920997A (enExample) |
| AU (2) | AU2016279997B2 (enExample) |
| CA (1) | CA2989581A1 (enExample) |
| EA (1) | EA201890068A1 (enExample) |
| HK (1) | HK1254054A1 (enExample) |
| IL (1) | IL256296A (enExample) |
| MA (1) | MA42196A (enExample) |
| MX (1) | MX387092B (enExample) |
| WO (1) | WO2016205270A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3368030A4 (en) * | 2015-10-28 | 2019-05-01 | Sun Pharmaceutical Industries Limited | PHARMACEUTICAL COMPOSITIONS OF DIMETHYLFUMARATE |
| JP6902043B2 (ja) | 2016-02-11 | 2021-07-14 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | フマル酸ジメチルを含む医薬ビーズ製剤 |
| EP3691616A1 (en) * | 2017-10-02 | 2020-08-12 | Novartis AG | Method for preparing a pharmaceutical product |
| US11318682B2 (en) | 2018-04-06 | 2022-05-03 | Hewlett-Packard Development Company, L.P. | Three-dimensional (3D) object printing based on build material permeability |
| JP7564805B2 (ja) * | 2018-10-05 | 2024-10-09 | アイエスピー インヴェストメンツ エルエルシー | 水溶性セルロースエーテルを含有する平滑な高固形分フィルムコーティング組成物、その調製方法およびその使用方法 |
| TR201818293A2 (tr) * | 2018-11-30 | 2020-06-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Di̇meti̇l fumarat i̇çeren geci̇kmeli̇ salim sağlayan kapsül |
| EP3917500A2 (en) * | 2019-01-31 | 2021-12-08 | Elektrofi, Inc. | Particle formation and morphology |
| CA3134186A1 (en) * | 2019-03-20 | 2020-09-24 | Lyndra Therapeutics, Inc. | Coatings for gastric residence dosage forms |
| JP2022525926A (ja) * | 2019-03-20 | 2022-05-20 | リンドラ セラピューティクス， インコーポレイティド | 胃内滞留剤形用のカプセル及びカプセルコーティング |
| JP2023553274A (ja) * | 2020-11-18 | 2023-12-21 | エフビー－エイチアールエス リミテッド ライアビリティ カンパニー | ドフェチリド及びメキシレチンを含有する組成物並びにその使用 |
| US20220175812A1 (en) | 2020-12-03 | 2022-06-09 | Battelle Memorial Institute | Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery |
| AU2022253899A1 (en) | 2021-04-07 | 2023-10-26 | Battelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
| US20240269084A1 (en) | 2021-06-04 | 2024-08-15 | Zim Laboratories Limited | Delayed release compositions of dimethyl fumarate |
| US11590071B2 (en) * | 2021-07-06 | 2023-02-28 | King Abdulaziz University | Injectable drug delivery implant composition and method of use thereof |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| WO2025090498A1 (en) * | 2023-10-23 | 2025-05-01 | Isp Investments Llc | Encapsulated medium chain fatty acid salts and oral solid dosage forms derived therefrom |
| US12441996B2 (en) | 2023-12-08 | 2025-10-14 | Battelle Memorial Institute | Use of DNA origami nanostructures for molecular information based data storage systems |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2725623A1 (fr) | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os |
| US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| IL133196A0 (en) | 1999-11-29 | 2001-03-19 | Yissum Res Dev Co | Gastroretentive controlled release pharmaceutical dosage forms |
| DE10101307A1 (de) | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
| US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| ES2525497T3 (es) * | 2004-10-08 | 2015-10-09 | Forward Pharma A/S | Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico |
| JP5399715B2 (ja) | 2006-01-18 | 2014-01-29 | インテック ファーマ リミテッド | 薬剤の経口摂取用の送達デバイスを形成する方法および装置 |
| LT2276473T (lt) * | 2008-04-18 | 2017-02-27 | Intec Pharma Ltd. | Pailginto atpalaidavimo vaistų karbidopa/levodopa įvedimas |
| EP2379062A1 (en) * | 2009-01-09 | 2011-10-26 | Forward Pharma A/S | Pharmaceutical composition comprising one or more fumaric acid esters |
| DK2379063T4 (da) | 2009-01-09 | 2021-05-25 | Fwp Ip Aps | Farmaceutisk præparat omfattende en eller flere fumarsyreestere i en erosionsmatrix |
| NZ618178A (en) * | 2011-06-08 | 2016-03-31 | Biogen Ma Inc | Process for preparing high purity and crystalline dimethyl fumarate |
| RU2014125430A (ru) * | 2011-11-24 | 2015-12-27 | Синтон Бв | Контролируемое высвобождение частиц, содержащих диметилфумарат |
| WO2013119677A1 (en) * | 2012-02-07 | 2013-08-15 | Biogen Idec Ma Inc. | Pharmaceutical compositions containing dimethyl fumarate |
| US20150079180A1 (en) | 2013-09-18 | 2015-03-19 | Xenoport, Inc. | Nanoparticle compositions of dimethyl fumarate |
| US9840456B2 (en) * | 2013-09-25 | 2017-12-12 | Glenmark Pharmaceuticals Limited | Process for preparation of dimethyl fumarate |
| US10172794B2 (en) | 2013-12-13 | 2019-01-08 | Biogen Ma Inc. | Controlled release dosage form for once daily administration of dimethyl fumarate |
| CA2939990C (en) * | 2014-02-28 | 2018-07-10 | Banner Life Sciences Llc | Controlled release enteric soft capsules of fumarate esters |
-
2016
- 2016-06-15 JP JP2017565133A patent/JP2018517735A/ja active Pending
- 2016-06-15 KR KR1020187001091A patent/KR20180018711A/ko not_active Ceased
- 2016-06-15 MA MA042196A patent/MA42196A/fr unknown
- 2016-06-15 AU AU2016279997A patent/AU2016279997B2/en not_active Ceased
- 2016-06-15 WO PCT/US2016/037486 patent/WO2016205270A1/en not_active Ceased
- 2016-06-15 EP EP16733793.0A patent/EP3310341A1/en not_active Withdrawn
- 2016-06-15 CA CA2989581A patent/CA2989581A1/en active Pending
- 2016-06-15 US US15/737,011 patent/US11291642B2/en active Active
- 2016-06-15 HK HK18113117.1A patent/HK1254054A1/zh unknown
- 2016-06-15 CN CN201680047251.2A patent/CN107920997A/zh active Pending
- 2016-06-15 EA EA201890068A patent/EA201890068A1/ru unknown
- 2016-06-15 MX MX2017016509A patent/MX387092B/es unknown
-
2017
- 2017-12-13 IL IL256296A patent/IL256296A/en unknown
-
2021
- 2021-11-12 JP JP2021184469A patent/JP2022042512A/ja active Pending
-
2022
- 2022-01-12 AU AU2022200155A patent/AU2022200155A1/en not_active Abandoned
- 2022-02-22 US US17/677,204 patent/US20220362195A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA201890068A1 (ru) | 2018-09-28 |
| WO2016205270A8 (en) | 2017-01-19 |
| JP2018517735A (ja) | 2018-07-05 |
| MX387092B (es) | 2025-03-19 |
| CA2989581A1 (en) | 2016-12-22 |
| IL256296A (en) | 2018-02-28 |
| JP2022042512A (ja) | 2022-03-14 |
| AU2016279997B2 (en) | 2021-10-21 |
| WO2016205270A1 (en) | 2016-12-22 |
| MX2017016509A (es) | 2018-08-16 |
| US20190070143A1 (en) | 2019-03-07 |
| KR20180018711A (ko) | 2018-02-21 |
| US20220362195A1 (en) | 2022-11-17 |
| AU2022200155A1 (en) | 2022-02-10 |
| CN107920997A (zh) | 2018-04-17 |
| AU2016279997A1 (en) | 2018-01-18 |
| US11291642B2 (en) | 2022-04-05 |
| EP3310341A1 (en) | 2018-04-25 |
| HK1254054A1 (zh) | 2019-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA42196A (fr) | Particules de fumarate de diméthyle et leurs compositions pharmaceutiques | |
| ZA201802125B (en) | Pharmaceutical composition and application thereof | |
| MA50541A (fr) | Formulations pharmaceutiques | |
| IL264065A (en) | Oral gastroretentive formulations and uses thes thereof | |
| EP3426348A4 (en) | 3-DESOXY DERIVATIVE AND PHARMACEUTICAL COMPOSITIONS THEREOF | |
| DK3529248T3 (da) | Farmaceutiske sammensætninger | |
| EP3500255A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR EYE AND RELATED USE | |
| EP3541385A4 (en) | PHARMACEUTICAL FORMULATIONS | |
| MA42303A (fr) | Formulations pharmaceutiques | |
| EP3316685A4 (en) | Lyophilized Pharmaceutical Compositions | |
| MA49837A (fr) | Compositions pharmaceutiques | |
| PL3145508T3 (pl) | Nanocząstki klewidypiny i ich kompozycje farmaceutyczne | |
| DK3280447T3 (da) | Farmaceutiske formuleringer | |
| EP3337463A4 (en) | PHARMACEUTICAL FORMULATIONS | |
| EP3302483A4 (en) | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | |
| IL254711B (en) | History of diazepine-indole and medicinal preparations containing them | |
| PT3236938T (pt) | Composições farmacêuticas aquosas tópicas orais de flurbiprofeno e dexpantenol | |
| KR101809800B9 (ko) | 전복 내장 유래의 항알러지 효과를 가지는 펩타이드가 함유된 약학 조성물 | |
| EP3651800A4 (en) | HYPER COMPRESSED PHARMACEUTICAL FORMULATIONS | |
| EP3423041A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| EP3528818A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| MA42552A (fr) | Compositions pharmaceutiques de flurbiprofène et de tramadol | |
| MA43126A (fr) | Compositions pharmaceutiques de fumarate de diméthyle | |
| MA49625A (fr) | Compositions pharmaceutiques | |
| DK3558261T3 (da) | Farmaceutiske sammensætninger omfattende safinamid |